Short Communication
Atherosclerosis is Lessened by Glycine-Based Therapy that Stimulates Glutathione Production
Author(s): Richie Rich*
Lower circulating glycine levels are frequently linked to cardiovascular disease (CVD); however it is still unknown whether glycine has a causal or therapeutic function in atherosclerosis, the primary factor in most CVDs. Following the discovery that individuals with severe coronary artery disease (sCAD) had lower levels of circulating glycine, we looked into the possibility that glycine plays a causal role in atherosclerosis by altering the availability of glycine in atheroprone mice. We also assessed DT-109's potential for atheroprotection, a newly discovered glycine-based molecule with dual lipid and glucose-lowering characteristics. In apolipoprotein E-deficient (Apoe/) mice, glycine deprivation accelerated atherosclerosis development whereas glycine supplementation slowed it down (Rom O et al., 2016). The most notable atheroprotective benefits were shown with the use .. View More»
DOI:
10.14303/2250-9941.2022.27